Usefulness of trigeminal somatosensory evoked potentials to detect subclinical trigeminal impairment in multiple sclerosis patients

2009 ◽  
Vol 89 (6) ◽  
pp. 412-414 ◽  
Author(s):  
R. Bergamaschi ◽  
A. Romani ◽  
M. Versino ◽  
R. Callieco ◽  
D. Gaspari ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Somatosensory Evoked Potentials ◽  
Multiple Sclerosis Patients

Clinical Features Neuropsychological Disorders in Multiple Sclerosis Patients in Aspect Comorbidity

2016 ◽  
pp. 112-116
Author(s):  
Hennadii Chupryna ◽  
Nataliia Svyrydova ◽  
Tetiana Parnikoza
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Evoked Potentials ◽  
Somatosensory Evoked Potentials ◽  
Clinical Manifestations ◽  
Seizure Threshold ◽  
Eeg Mapping ◽  
Neuropsychological Disorders ◽  
Multiple Sclerosis Patients ◽  
The Brain

The objective: to investigate the relationship between clinical manifestations of neuropsychological disorders and neuroimaging data (MRI) and electrophysiological (EEG mapping, somatosensory evoked potentials) methods of diagnosis in patients with multiple sclerosis (MS) in the aspect of comorbidity. Patients and methods. Achieved the clinical, neuropsychological, instrumental study 216 MS patients with the presence of (107) or absence (109) comorbid pathology. Spend a numerical score of neurological deficit symptoms (the FS scale) with the total score counting, defined EDSS level evaluated symptoms of fatigue (the FSS), pain (VAS), depression (BDI-II), the degree of cognitive impairment (MMSE). Implemented neyrovizualizuatsionnoe (MRI) study of the brain and spinal cord and EEG mapping study of electrical activity (EA) of the brain., somatosensory evoked potentials (SSEP). Results. It is found that the presence of foci of demyelination in the brain stem in both groups correlated with the severity of the manifestations of depression BDI-II data. It also shows that about 65% of both groups of MS patients had signs of decrease ascending activating effects on the cortex from the reticular formation of the brainstem. It was found that 70% of MS patients in both groups there are irritative and hypersynchronous types EA brain, reducing the symptoms of seizure threshold, with the presence of a strong direct correlation between them and multimodal pain. Conclusions. In the presence of comorbid disease in MS patients observed clinically deeper and more frequent manifestations of NPM, which is confirmed by the results of neuropsychological testing conducted. The presence of foci of demyelination in the cervical spinal cord was significantly more frequent in the MS group with comorbidity (p<0.05), and both groups of patients clinically directly correlates with the severity of pain according to VAS.

Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy

2016 ◽  
Vol 365 ◽  
pp. 143-146 ◽  
Author(s):  
R. Iodice ◽  
A. Carotenuto ◽  
R. Dubbioso ◽  
I. Cerillo ◽  
L. Santoro ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Multimodal Evoked Potentials ◽  
Multiple Sclerosis Patients

MRI and visual-evoked potentials in partners of multiple sclerosis patients

2011 ◽  
Vol 125 (6) ◽  
pp. 424-430 ◽  
Author(s):  
C. H. Hawkes ◽  
S. Chawda ◽  
S. Derakshani ◽  
N. Muhammed ◽  
E. Visentin ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Visual Evoked Potentials ◽  
Multiple Sclerosis Patients ◽  
Visual Evoked

scholarly journals Еvaluation data somatosensory evoked potentials and electromyography in patients with multiple sclerosis in the aspect comorbidity

2017 ◽  
pp. 22-29
Author(s):  
G. Chupryna ◽  
N. Svyrydova ◽  
T. Parnikoza
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Somatosensory Evoked Potentials ◽  
Clinical Signs ◽  
Pain Syndrome ◽  
Pathological Process ◽  
Psychological Status ◽  
Sensorimotor Polyneuropathy ◽  
Initial Stage ◽  
Prevalence Of Pain

The paper shows the results of electrophysiological methods of investigation in patients with multiple sclerosis (MS) in the aspect of comorbidity. The studies of somatosensory evoked potentials (SSEP) in 216 patients with MS and electroneuromyography in 158 patients with MS, together with the assessment of neurological and psychological status. It is shown that according SSEP increase latency peripheral response in a progressive course of MS compared to remitting associated with older age of patients with progressive MS, and due to involvement in the pathological process of the peripheral nervous system (PNS) and the prevalence of pain syndrome (PS) in patients MS with comorbidity. It is demonstrated, on the basis of electroneuromyographic that MS patients with comorbidity tends to be deeper shock PNS. The data electroneuromyographic clinically appropriate initial stage of sensory or sensorimotor polyneuropathy, which proceeded in 84.8% of patients with MS subclinical and 15.2% had a clear clinical signs.

Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis

2010 ◽  
Vol 17 (2) ◽  
pp. 198-203 ◽  
Author(s):  
Sven G Meuth ◽  
Stefan Bittner ◽  
Carola Seiler ◽  
Kerstin Göbel ◽  
Heinz Wiendl
Keyword(s):  
Multiple Sclerosis ◽  
Evoked Potentials ◽  
Motor Evoked Potentials ◽  
Sum Score ◽  
Relapsing Remitting ◽  
Natalizumab Treatment ◽  
Remitting Multiple Sclerosis ◽  
Sum Scores ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Background and Objective: The objective of this study was to examine the effects of natalizumab on functional parameters assessed by evoked potentials (visual [VEP], somatosensory [SEP] and motor evoked potentials [MEP]) in a cohort study in relapsing–remitting multiple sclerosis patients. Methods: EP data of 44 patients examined 12 months prior to natalizumab treatment, at the timepoint of treatment initiation and 1 year later were compared. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the Expanded Disability Status Scale. Results: Improvement of the VEP sum score was found in 33% of natalizumab-treated patients but only in 9% of the same patients prior to treatment ( p = 0.041). A comparable situation was found for SEP (improvement: 32% versus 5%; worsening: 11% versus 37%; p = 0.027). For MEP no significant differences were seen (improvement: 10% versus 18%; worsening: 5% versus 29%; p = 0.60). EP recordings (VEP = SEP > MEP) have the capacity to demonstrate treatment effects of natalizumab on a functional level. Conclusions: Natalizumab therapy increases the percentage of patients showing stable or even ameliorated electrophysiological parameters in the investigated functional systems.

Sign in / Sign up

Export Citation Format

Share Document